). or not to participate. It is also a continuing process throughout the study to provide information for participants. To
a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study.
assignment. See Blind or a disease) over a period of time.
: The processes (in a living organism) of absorption, distribution, metabolism, and excretion of a drug or vaccine.
TRIALS: Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects
to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.
currently in wide use and approved by the FDA, considered to be effective in the treatment of a specific disease or condition.
whether it can be achieved without raising the retirement age as a requirement for the entitlement to old age pension, or lifting the contribution rates for pension insurance. To this end, the paper analyzed certain provisions of the
i vinogradarskog sadnog materijala vrhunske kvalitete, iz godine u godinu podiže nove nasade tako da danas ima or ...
ima 22 % manji omjer šansi rizika za hospitalizaciju zbog akutne koronarne bolesti u odnosu na nemanuelnog radnika ( OR = 0,78,95 %, CI 0,61 0,99, p = 0,0382).
nastanka AIM. Učestalost AIM u tjednima nakon PLJRV i PZRV u odnosu na ostale tjedne izražena je putem omjera šanse ( OR ) sa pripadajućim 95 % - tnim intervalom pouzdanosti (CI). Rezultati: Tijekom prvog tjedna nakon PLJRV, AIM je bio
95 % - tnim intervalom pouzdanosti (CI). Rezultati: Tijekom prvog tjedna nakon PLJRV, AIM je bio značajno učestaliji ( OR = 1.15, 95 % CI 1.04 1.26) kao i nakon PZRV (OR = 1.19, 95 % CI 1.07 1.28). Bolesnici hospitalizirani u tjednu nakon PLJRV, u
: Tijekom prvog tjedna nakon PLJRV, AIM je bio značajno učestaliji (OR = 1.15, 95 % CI 1.04 1.26) kao i nakon PZRV ( OR = 1.19, 95 % CI 1.07 1.28). Bolesnici hospitalizirani u tjednu nakon PLJRV, u odnosu na ostala razdoblja tijekom godine
u tjednu nakon PLJRV, u odnosu na ostala razdoblja tijekom godine, statistički neznačajno češće su bili muškarci ( OR = 1.71, 95 % CI 0.88 3.35), a rjeđe su bili hipertoničari (OR = 0.68, 95 % CI 0.38 1.21) ili u terapiji imali
godine, statistički neznačajno češće su bili muškarci (OR = 1.71, 95 % CI 0.88 3.35), a rjeđe su bili hipertoničari ( OR = 0.68, 95 % CI 0.38 1.21) ili u terapiji imali acetilsalicilat (OR = 0.60, 95 % CI 0.27 1.33) ili kalcijski antagonist (OR